About Us

Tiberend Strategic Advisors, Inc. (Tiberend) is a full service corporate communications firm specializing in the healthcare and life sciences industry. Founded in 1989, Tiberend’s mission is to provide expert public and investor relations counsel to companies along the entire development lifecycle – from emerging, clinical-stage to publicly traded, revenue generating.


Tiberend creates individualized platforms for companies to communicate their value proposition to those audiences that have the greatest influence on their growth and success – investors, industry stakeholders, customers and the media.


Our goal is to be an integral component of our clients’ business, whether the aim is to complete a round of financing, secure a partner, advance a clinical trial or commercialize a newly launched product.


The Right Message to the Right Audience at the Right Time.

The Tiberend Team:

Gregory Q. Tiberend – President & CEO


Greg has 35+ years experience counseling senior management and has developed and executed strategic corporate communications programs for publicly traded and private companies. Greg co-founded Richard Lewis Communications, Inc. in 1989 and spent 10 years building the business and rejoined the firm in June 2005. In May 2008, Greg became president & CEO. In 2009, the firm’s name was changed to Tiberend Strategic Advisors, Inc.


Prior to re-joining the firm, Greg spent three years leading the healthcare practice as Executive Vice President at The Ruth Group where he built significant revenue for the life sciences group and counseled senior management on investor communications programs.


From 1999 to 2002, Greg was a Vice President at Morgen-Walke Associates, Inc. (now Financial Dynamics) where he led multiple practice areas – healthcare and business services. Early in his career, Greg was Communications Manager for American Cyanamid’s International Agricultural Division where he worked on a global basis with country managers in developing and building communications programs for animal health biologics and crop protection chemicals.


Having developed strong relationships during his career with investment bankers, venture capitalist and journalists, Greg has counseled more than 200 companies in the areas of biotechnology, specialty pharmaceutical, generic pharmaceutical, medical device, medical technology, diagnostics, healthcare services and financial services. He has a strong understanding of the stories investors and journalists are seeking and works with clients to develop key messages to best that will resonate with multiple audiences including investors and potential partners.


Greg is a 1984 graduate of the University of Illinois at Urbana-Champaign.


Jason Rando – Executive Vice President & Chief Operating Officer


Jason is responsible for guiding the firm’s strategic direction as well as the day-to-day management of its clients’ investor communications and public relations programs. From media visibility to product marketing to patient and physician education, Jason works with the Tiberend team to design individualized communications programs that enable the firm’s clients to direct their message to the audiences most integral to the growth of their business.


With 25+ years industry experience, Jason has specialized in establishing and managing high-level communications programs for public and private companies in a number of industries, including healthcare (biotech, pharmaceutical, medical technology), financial services and technology. During Jason’s career, his close ties with the top-tier national media have generated significant client exposure, including feature coverage in The Wall Street Journal, The New York Times, Bloomberg BusinessWeek, Dow Jones, Reuters, Forbes, Fortune, Investor’s Business Daily, and 300+ executive and financial analyst interviews on CNBC.


Prior to joining Tiberend Strategic Advisors, Jason spent nine years at The Ruth Group with increasing levels of responsibility, most recently as Senior Vice President, Public Relations and Healthcare Marketing.


Jason is a 1994 graduate of Tufts University with a degree in psychology.


Johanna Bennett – SVP, Public Relations


As a veteran financial journalist, Johanna knows the value of good storytelling. At Tiberend, she uses her passion and skills to develop and execute communication strategies and media relations programs to tell stories that enhance reputations and drive business goals for life sciences companies across the development spectrum.


Prior to joining Tiberend, Johanna served as an Associate Director at Finsbury, working with Fortune 500 companies and development-stage drug makers on strategic messaging and media strategies for clinical data, annual investor meetings, product launches, crisis management, and business development. For 20 years, she reported on financial markets and covered blue-chip health care companies for Barron’s and Dow Jones Newswires, where she won two Front Page Awards from the Newswomen’s Club of New York. Her relationships include reporters with top-tier national news and financial media outlets including Barron’s, Business Insider, The Wall Street Journal, Bloomberg and Reuters.


Johanna is a graduate of Rhode Island College with degrees in English Literature and Political Science.


Johanna Bennett

Lisa Sher – SVP, Investor Relations


Lisa has spent more than 15 years helping life sciences companies tell their story to the right audience at the right time. She has served as in-house Head of Investor Relations for private and publicly traded companies in a multitude of therapeutic areas including, but not limited to CNS, oncology, rare disease, anti-infectives and addiction. In addition to providing senior-level in-house investor relations and communications counsel, Lisa has spent many years on the agency side with healthcare focused investor and media relations firms.


Earlier in her IR career, she served as Director, Investor Relations & Programming for the Biotechnology Innovation Organization, also known as BIO. At BIO, Lisa led all investor communications and initiated and implemented several new programs to further engage the investment community in the organization. In the early 2000s, Lisa was in the top ranks of pharmaceutical sales reps at industry leaders; Schering-Plough (acquired by Merck), Astra Zeneca and Endo Pharmaceuticals.


In addition to her expertise in healthcare, Lisa serves on the National Board of Directors for Cents Ability, a nonprofit organization dedicated to educating and empowering high school students to achieve their goals through the prudent and informed management of their financial resources.


Lisa holds a Bachelor of Arts in International Relations with honors from Boston University.